Free tool
FAERS Monitor: Tagrisso
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208065 or its brand name (Tagrisso, Osimertinib Mesylate). Reports on generic versions are filed under their own applications.
Reports
33,148
Serious
31,031
94% of reports
Hospitalization
6,284
Death reported
14,432
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death11,742
- malignant neoplasm progression3,446
- diarrhoea1,744
- fatigue1,121
- drug resistance1,112
- rash988
- off label use830
- decreased appetite829
- disease progression790
- dyspnoea784
- drug ineffective762
- nausea747
- asthenia703
- metastases to central nervous system671
- interstitial lung disease602
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 35 |
| 2016 | 685 |
| 2017 | 1,070 |
| 2018 | 1,424 |
| 2019 | 2,252 |
| 2020 | 3,363 |
| 2021 | 3,455 |
| 2022 | 3,423 |
| 2023 | 4,350 |
| 2024 | 4,988 |
| 2025 | 4,204 |
| 2026 | 3,897 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,021,011 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| metastases to central nervous systemSignal | 671 | 34.8 | 32.2 | 20,841 |
| drug resistanceSignal | 1,112 | 28.7 | 27.0 | 28,414 |
| malignant neoplasm progressionSignal | 3,446 | 22.1 | 21.4 | 67,257 |
| deathSignal | 11,742 | 8.8 | 8.6 | 82,934 |
| interstitial lung diseaseSignal | 602 | 8.0 | 7.4 | 3,629 |
| disease progressionSignal | 790 | 4.3 | 4.0 | 1,964 |
| decreased appetiteSignal | 829 | 2.3 | 2.1 | 592 |
| diarrhoea | 1,744 | 1.7 | 1.6 | 536 |
| rash | 988 | 1.4 | 1.4 | 134 |
| asthenia | 703 | 1.2 | 1.1 | 21 |
| fatigue | 1,121 | 0.9 | 0.9 | 9 |
| dyspnoea | 784 | 0.9 | 0.8 | 13 |
| off label use | 830 | 0.6 | 0.6 | 229 |
| nausea | 747 | 0.6 | 0.6 | 208 |
| drug ineffective | 762 | 0.4 | 0.3 | 889 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.